Close Menu

NEW YORK (GenomeWeb News) – SQI Diagnostics and Algorithme Pharma today said they are co-developing a proof-of-concept assay for immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

The assay is based on SQI's Ig Plex multiplexing technology and is expected to be available on all of the Toronto-based firm's fully automated analytical systems, including its SQIDlite and SQIDworks platforms.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.